Biblio Discovery — Demo Discovery Service

29 hasil untuk "Abdullahi Adam"

Menampilkan 21–29 · 0,78 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression

    Kamelian, Kimia; Sievers, Benjamin; Chen-Xu, Michael dkk.

    Sci Adv · 2025 · Inggris · PubMed Central

    Immune suppression poses a challenge to vaccine immunogenicity. We show that serum antibody neutralization against SARS-CoV-2 Omicron descendants was largely absent post-doses 1 and 2 in individuals with vasculitis treated with rituximab. Detectable and increasing neutralizing titers were observed…

  2. Artikel Jurnal Teks lengkap

    Sero-genomic evidence for occult mpox exposure in healthy Nigerian adults

    Abdullahi, Adam; Omah, Ifeanyi; Kassanjee, Reshma dkk.

    Nat Commun · 2026 · Inggris · PubMed Central

    The 2022 multi-country mpox (formerly monkeypox) outbreak, driven by mpox virus (MPXV) Clade IIb poses renewed threat to global public health. The cessation of smallpox vaccination has created large immunologically naïve cohorts, with uncertain implications for contemporary MPXV susceptibility. To…

  3. Artikel Jurnal Teks lengkap

    Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

    Collier, Dami A.; Ferreira, Isabella A. T. M.; Kotagiri, Prasanti dkk.

    Nature · 2021 · Inggris · PubMed Central

    Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age(1). Here we analysed immune responses following vaccination with the BNT162b2 mRNA…

  4. Artikel Jurnal Teks lengkap

    Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial

    Salako, Abideen; Musa, Adesola; Ige, Fehintola dkk.

    Sci Rep · 2025 · Inggris · PubMed Central

    Fractional dosing of vaccines is a viable strategy to extend COVID-19 vaccine supplies in resource-constrained settings. We did a triple-blinded, multi-site, randomized non-inferiority trial in Nigeria (PACTR202206754734018). Adults 18–65 years received full, half, or quarter primary doses of…

  5. Artikel Jurnal Teks lengkap

    Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly

    Ferreira, Isabella A.T.M.; Lee, Colin Y.C.; Foster, William S. dkk.

    Cell Rep · 2023 · Inggris · PubMed Central

    Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70–75) who received a primary two-dose…

  6. Artikel Jurnal Teks lengkap

    SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa

    Abdullahi, Adam; Oladele, David; Owusu, Michael dkk.

    Nat Commun · 2022 · Inggris · PubMed Central

    Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using binding antibodies analysis coupled with…

  7. Artikel Jurnal Teks lengkap

    SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

    Mlcochova, Petra; Kemp, Steven A.; Dhar, Mahesh Shanker dkk.

    Nature · 2021 · Inggris · PubMed Central

    The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)(1). In vitro, B.1.617.2 is…

  8. Artikel Jurnal Teks lengkap

    Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

    Meng, Bo; Abdullahi, Adam; Ferreira, Isabella A. T. M. dkk.

    Nature · 2022 · Inggris · PubMed Central

    The SARS-CoV-2 Omicron BA.1 variant emerged in 2021(1) and has multiple mutations in its spike protein(2). Here we show that the spike protein of Omicron has a higher affinity for ACE2 compared with Delta, and a marked change in its antigenicity increases Omicron’s evasion of therapeutic monoclonal…